
The Portfolio Imperative: Converting AI Investment into Compounding Enterprise Value
To convert your AI ambitions into compounding enterprise value, biopharma leaders must shift from managing a collection of pilots to operating a disciplined portfolio system. This article explores Scimitar’s “AI Value Operating Flywheel,” outlining the structural decisions, governance archetypes, and strategic allocation variables required to ensure AI investments deliver measurable, long-term impact.
